This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

GLP1 analogues

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • first antidiabetic medication based on the incretin hormone glucagon-like peptide-1 (GLP-1) was approved in 2005 (exenatide) as an adjunctive therapy in diabetic patients in whom sulphonylurea, metformin or both had failed
  • since exenatide, there has been the introduction of subsequent incretin mimetics in the UK. Liraglutide is available to prescribe as a once daily preparation. There is also available a once weekly preparation of exenatide; as well as the other once weekly incretin mimetics - dulaglutide and semaglutide.

    • the ability of GLP-1 to enhance pancreatic ß-cell mass could delay progression of the disease - however, only several years of treatment in humans will confirm the long-term efficacy of GLP-1 mimetics and enhancers on glycemic control
    • gastrointestinal glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are 'incretin hormones' released from the gut after a meal and are responsible for 70% of postprandial insulin secretion
      • a 31 amino acid peptide - GLP-1 is cleaved from proglucagon in L-cells in the GI-tract (and neurons in hindbrain/hypothalamus)
      • secreted in response to meal ingestion (direct luminal and indirect neuronal stimulation)
      • there is impairment of GLP-1 secretion and GIP action in diabetic patients - incretin effect is decreased to 30%
      • GLP-1 stimulates insulin secretion, glucose-dependently
      • GLP-1 decreases glucagon secretion, glucose-dependently
      • delays gastric emptying, decreases food intake and body weight
      • GLP-1 can enhance pancreatic ß-cell mass through the stimulation of ß-cell proliferation and neogenesis in healthy and diabetic rodents
      • GIP
        • has a similar insulinotropic effect to GLP-1 at glucose concentrations between 5.5 mM and 7.8 mM
        • GIP does not suppress glucagon secretion, and its effects on feeding behavior, if any, are unknown
      • collectively, these characteristics render GLP-1 more attractive than GIP as a target for the treatment of type 2 diabetes
        • GLP-1 is rapidly degraded by dipeptidylpeptidase IV (DPPIV)
          • therefore two approaches to utilization of the incretin effect were undertaken:
            • development of GLP-1 analogues (GLP-1 mimetics) resistant to degradation by DPPIV or the development of DPPIV inhibitors
    • GLP-1 analogues (GLP-1 mimetics)
      • lead to delayed gastric emptying, body weight loss
      • circulating concentrations of GLP-1 that induce nausea can be reached after subcutaneous injection of GLP-1 mimetics, but are not seen with DPPIV inhibitors
      • GLP-1 mimetics, which slow gastric emptying, might not only reduce the extent and rate of absorption of nutrients but also that of orally administered drugs - therefore be used with caution in patients receiving oral medications that require rapid gastrointestinal absorption and threshold concentrations for efficacy
      • main advantage of GLP-1 mimetics is their induction of weight loss, in addition to improvements in glycaemic control

    • Cardiovascular endpoints and GLP-1 mimetics:
    • regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk. The cardiovascular safety of GLP-1 mimetics has therefore been investigated in formal clinical trials. Of note is that there is evidence of cardiovascular benefit with treatment with liraglutide (LEADER), dulaglutide (REWIND) and semaglutide (SUSTAIN-6). See linked items for details.

Notes:

  • pancreatitis and renal failure
    • there have been reports of necrotising and haemorrhagic pancreatitis in people taking exenatide some of which were fatal - stop exenatide treatment if pancreatitis is diagnosed (2)

  • GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued (3)
    • diabetic ketoacidosis has been reported in patients with type 2 diabetes on a combination of a GLP-1 receptor agonist and insulin who had doses of concomitant insulin rapidly reduced or discontinued. GLP-1 receptor agonists are not substitutes for insulin, and any reduction of insulin should be done in a stepwise manner with careful glucose self-monitoring. Abrupt discontinuation or reduction in insulin doses can lead to poor glycaemic control, with a risk of diabetic ketoacidosis

  • GLP-1 receptor agonists and metformin
    • analysis (n=16,996) of four clinical trials investigating GLP-1 receptor agonists (RA) found concomitant metformin use did not increase the percentage of patients who developed GI adverse effects or their severity during GLP-1RA initiation or discontinuation (4)

Reference:

  1. Curr Opin Pharmacol. 2006 Dec;6(6):598-605.
  2. MHRA (December 2014). Exenatide: risk of severe pancreatitis and renal failure
  3. MHRA (June 2019). GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
  4. Klein KR et al. Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN 6, and PIONEER 6. Diabetes Care 2023; dc231791.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.